Patents by Inventor Takashi Matozaki

Takashi Matozaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210155707
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Application
    Filed: July 9, 2019
    Publication date: May 27, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takashi MATOZAKI, Mayumi SUE, Kensuke NAKAMURA, Chigusa YOSHIMURA
  • Publication number: 20190153095
    Abstract: Provided is an antitumor agent targeting SIRP?, which inhibits binding between CD47 and SIRP?, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRP?. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRP? protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect.
    Type: Application
    Filed: June 27, 2017
    Publication date: May 23, 2019
    Inventors: Takashi MATOZAKI, Yoji MURATA
  • Patent number: 7449301
    Abstract: A pharmaceutical composition is produced by obtaining an antibody which specifically recognizes an extracellular domain of SIRP? and formulating the antibody with a pharmaceutical acceptable carrier. The patient suffering from infectious disease or cancer is treated by administering the pharmaceutical composition to activate macrophages.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: November 11, 2008
    Assignee: National University Corporation Gunma University
    Inventors: Takashi Matozaki, Hiroshi Ohnishi
  • Publication number: 20060135749
    Abstract: A CD47 partial peptide which has an amino acid sequence constituting an extracellular region having an immunoglobulin-like structure of a CD47 protein, which is specifically bound to an N-terminal immunoglobulin-like structure of a dephosphorylation substrate protein SHPS-1 of an SH2 domain-containing protein, and which can act on a function of cell response mediated by SHPS-1, and an anti-SHPS-1 monoclonal antibody.
    Type: Application
    Filed: May 31, 2004
    Publication date: June 22, 2006
    Inventors: Takashi Matozaki, Hideki Okazawa
  • Publication number: 20050244415
    Abstract: A pharmaceutical composition is produced by obtaining an antibody which specifically recognizes an extracellular domain of SIRP? and formulating the antibody with a pharmaceutical acceptable carrier. The patient suffering from infectious disease or cancer is treated by administering the pharmaceutical composition to activate macrophages.
    Type: Application
    Filed: November 23, 2004
    Publication date: November 3, 2005
    Inventors: Takashi Matozaki, Hiroshi Ohnishi